In-depth clinical and biological exploration of DNA Damage Immune Response (DDIR) as a biomarker for oxaliplatin use in colorectal cancer.
CONCLUSIONS: DDIR positivity does not predict improved response following oxaliplatin treatment in CRC. However, data presented here suggests the potential of the DDIR assay in identifying immune-rich tumours that may benefit from immune checkpoint blockade, beyond current use of MSI status.
PMID: 33028592 [PubMed - as supplied by publisher]
Source: Clinical Cancer Research - Category: Cancer & Oncology Authors: Malla SB, Fisher D, Domingo E, Blake A, Hassanieh S, Redmond KL, Richman SD, Youdell M, Walker S, Logan GE, Chatzipli A, Amirkhah R, Humphries MP, Craig SG, McDermott U, Seymour MT, Morton DG, Quirke P, West NP, Salto-Tellez M, Kennedy RD, Johnston PG, To Tags: Clin Cancer Res Source Type: research
More News: Anemia | Biology | Breast Cancer | Cancer | Cancer & Oncology | Chemotherapy | Colorectal Cancer | Eloxatin | Esophagus Cancer | Faconi Anemia | Legislation | Molecular Biology